74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Intra-Cellular Therapies Inc
Closed
Sector Healthcare
128.59 0.05
Overview
Share price change
24h
Min
128.53
Max
128.61
Income | -10M -26M |
|---|---|
Sales | 14M 175M |
EPS | -0.25 |
Profit margin | -15.029 |
Employees | 610 |
EBITDA | -11M -39M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +0.67 upside |
Next Earnings | 6 May 2025 |
|---|
Market Cap | 1.4B 14B |
|---|---|
Previous open | 128.54 |
Previous close | 128.59 |
News Sentiment
By Acuity
67%
33%
346 / 393 Healthcare
Technical Score
By Trading Central
Confidence
Weak Bearish Evidence
Intra-Cellular Therapies Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Intra-Cellular Therapies Inc Forecast
Price Target
By TipRanks
0.67% upside
12 Months Forecast
Average 129.46 USD 0.67%
High 140 USD
Low 105 USD
Based on 14 Wall Street analysts offering 12 month price targets forIntra-Cellular Therapies Inc - Dist in the last 3 months.
Sentiment
By Acuity
346 / 393 Healthcare
News Sentiment
Bearish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Intra-Cellular Therapies Inc
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
